Hepatotoxicity epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 8: | Line 8: | ||
==Epidemiology== | ==Epidemiology== | ||
Drug-induced liver injury (DILI) has an approximate annual incidence between 10 and 15 per 10,000 to 100,000 persons. More than a thousand drugs have been associated with DILI, the most common among them are antimicrobial agents and drugs work on the central venous system.<ref name="Chalasani-2008">{{Cite journal | last1 = Chalasani | first1 = N. | last2 = Fontana | first2 = RJ. | last3 = Bonkovsky | first3 = HL. | last4 = Watkins | first4 = PB. | last5 = Davern | first5 = T. | last6 = Serrano | first6 = J. | last7 = Yang | first7 = H. | last8 = Rochon | first8 = J. | last9 = Chalasani | first9 = N. | title = Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. | journal = Gastroenterology | volume = 135 | issue = 6 | pages = 1924-34, 1934.e1-4 | month = Dec | year = 2008 | doi = 10.1053/j.gastro.2008.09.011 | PMID = 18955056 }}</ref> | |||
Drug-induced liver injury (DILI) has an approximate annual incidence between 10 and 15 per 10,000 to 100,000 persons. One study from France reported a crude annual incidence of 13.9 ± 2.4 per 100,000 inhabitants, which is 16 times greater than the number noted by spontaneous reporting to French regulatory authorities.<ref name="Sgro-2002">{{Cite journal | last1 = Sgro | first1 = C. | last2 = Clinard | first2 = F. | last3 = Ouazir | first3 = K. | last4 = Chanay | first4 = H. | last5 = Allard | first5 = C. | last6 = Guilleminet | first6 = C. | last7 = Lenoir | first7 = C. | last8 = Lemoine | first8 = A. | last9 = Hillon | first9 = P. | title = Incidence of drug-induced hepatic injuries: a French population-based study. | journal = Hepatology | volume = 36 | issue = 2 | pages = 451-5 | month = Aug | year = 2002 | doi = 10.1053/jhep.2002.34857 | PMID = 12143055 }}</ref> The true incidence of hepatic adverse events in the general population remains unknown and is often underestimated. More than a thousand drugs have been associated with DILI, the most common among them are antimicrobial agents and drugs work on the central venous system.<ref name="Chalasani-2008">{{Cite journal | last1 = Chalasani | first1 = N. | last2 = Fontana | first2 = RJ. | last3 = Bonkovsky | first3 = HL. | last4 = Watkins | first4 = PB. | last5 = Davern | first5 = T. | last6 = Serrano | first6 = J. | last7 = Yang | first7 = H. | last8 = Rochon | first8 = J. | last9 = Chalasani | first9 = N. | title = Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. | journal = Gastroenterology | volume = 135 | issue = 6 | pages = 1924-34, 1934.e1-4 | month = Dec | year = 2008 | doi = 10.1053/j.gastro.2008.09.011 | PMID = 18955056 }}</ref> | |||
It has been suggested that for every 10 cases of elevations in [[alanine aminotransferase|alanine aminotransferase (ALT)]] in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.<ref name="Maddur-2011">{{Cite journal | last1 = Maddur | first1 = H. | last2 = Chalasani | first2 = N. | title = Idiosyncratic drug-induced liver injury: a clinical update. | journal = Curr Gastroenterol Rep | volume = 13 | issue = 1 | pages = 65-71 | month = Feb | year = 2011 | doi = 10.1007/s11894-010-0154-8 | PMID = 21049293 }}</ref><ref name="Lewis-2006">{{Cite journal | last1 = Lewis | first1 = JH. | title = 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. | journal = Pharmacoepidemiol Drug Saf | volume = 15 | issue = 4 | pages = 221-9 | month = Apr | year = 2006 | doi = 10.1002/pds.1209 | PMID = 16444771 }}</ref> | It has been suggested that for every 10 cases of elevations in [[alanine aminotransferase|alanine aminotransferase (ALT)]] in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.<ref name="Maddur-2011">{{Cite journal | last1 = Maddur | first1 = H. | last2 = Chalasani | first2 = N. | title = Idiosyncratic drug-induced liver injury: a clinical update. | journal = Curr Gastroenterol Rep | volume = 13 | issue = 1 | pages = 65-71 | month = Feb | year = 2011 | doi = 10.1007/s11894-010-0154-8 | PMID = 21049293 }}</ref><ref name="Lewis-2006">{{Cite journal | last1 = Lewis | first1 = JH. | title = 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. | journal = Pharmacoepidemiol Drug Saf | volume = 15 | issue = 4 | pages = 221-9 | month = Apr | year = 2006 | doi = 10.1002/pds.1209 | PMID = 16444771 }}</ref> | ||
==References== | ==References== | ||
Revision as of 20:45, 11 February 2014
|
Hepatotoxicity Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatotoxicity epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatotoxicity epidemiology and demographics |
|
Risk calculators and risk factors for Hepatotoxicity epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Overview
Drug-related hepatotoxicity is generally considered as an uncommon complication for many drugs, with an incidence between 1 in 10,000 and 1 in 100,000.[1] The true incidence of drug-induced liver injury is hard to determine, partly because of difficulties in detection as well as lack of unified criteria for diagnosis.
Epidemiology
Drug-induced liver injury (DILI) has an approximate annual incidence between 10 and 15 per 10,000 to 100,000 persons. One study from France reported a crude annual incidence of 13.9 ± 2.4 per 100,000 inhabitants, which is 16 times greater than the number noted by spontaneous reporting to French regulatory authorities.[2] The true incidence of hepatic adverse events in the general population remains unknown and is often underestimated. More than a thousand drugs have been associated with DILI, the most common among them are antimicrobial agents and drugs work on the central venous system.[3]
It has been suggested that for every 10 cases of elevations in alanine aminotransferase (ALT) in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.[4][5]
References
- ↑ Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. (2002). "Incidence of drug-induced hepatic injuries: a French population-based study". Hepatology. 36 (2): 451–5. doi:10.1053/jhep.2002.34857. PMID 12143055. Unknown parameter
|month=ignored (help) - ↑ Chalasani, N.; Fontana, RJ.; Bonkovsky, HL.; Watkins, PB.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J.; Chalasani, N. (2008). "Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States". Gastroenterology. 135 (6): 1924–34, 1934.e1–4. doi:10.1053/j.gastro.2008.09.011. PMID 18955056. Unknown parameter
|month=ignored (help) - ↑ Maddur, H.; Chalasani, N. (2011). "Idiosyncratic drug-induced liver injury: a clinical update". Curr Gastroenterol Rep. 13 (1): 65–71. doi:10.1007/s11894-010-0154-8. PMID 21049293. Unknown parameter
|month=ignored (help) - ↑ Lewis, JH. (2006). "'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective". Pharmacoepidemiol Drug Saf. 15 (4): 221–9. doi:10.1002/pds.1209. PMID 16444771. Unknown parameter
|month=ignored (help)